Martin Wisher, PhD Merck BioReliance

Dr Wisher has more than 34 years’ experience in biosafety testing, validation and regulatory affairs. He has worked for BioReliance, UK, for 29 years, since the company was founded in Stirling in 1990, acting as Scientific Director since 1993.

Martin has extensive experience in the technical, scientific, quality and regulatory aspects of biological product quality control and manufacture. 

Prior to joining BioReliance, Dr Wisher worked for Inveresk Research as Manager of Immunology, responsible for biosafety services.

He obtained a PhD in membrane biochemistry from the National Institute for Medical Research, London, and prior to moving to the contract research industry was involved in research on membrane receptors, monoclonal antibodies and recombinant vaccines.

Martin is a member of the PDA Regulatory Affairs & Quality Advisory Board (RAQAB), a member of the Alliance for Regenerative Medicine (ARM) European Regulatory Affairs Committee, Deputy Chairperson of the Animal Cell Technology Industrial Platform (ACTIP) and member of Biophorum Cell & Gene Therapy Regulatory Strategy Working Group.